Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LENALIDOMIDE Cause Plasma cell myeloma recurrent? 1,501 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,501 reports of Plasma cell myeloma recurrent have been filed in association with LENALIDOMIDE (LENALIDOMIDE). This represents 0.4% of all adverse event reports for LENALIDOMIDE.

1,501
Reports of Plasma cell myeloma recurrent with LENALIDOMIDE
0.4%
of all LENALIDOMIDE reports
139
Deaths
285
Hospitalizations

How Dangerous Is Plasma cell myeloma recurrent From LENALIDOMIDE?

Of the 1,501 reports, 139 (9.3%) resulted in death, 285 (19.0%) required hospitalization, and 32 (2.1%) were considered life-threatening.

Is Plasma cell myeloma recurrent Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LENALIDOMIDE. However, 1,501 reports have been filed with the FAERS database.

What Other Side Effects Does LENALIDOMIDE Cause?

Diarrhoea (27,576) Fatigue (22,956) Death (19,213) Off label use (17,017) Rash (15,794) Pneumonia (14,807) Plasma cell myeloma (14,191) Neuropathy peripheral (10,215) White blood cell count decreased (9,996) Constipation (9,635)

What Other Drugs Cause Plasma cell myeloma recurrent?

BORTEZOMIB (995) DEXAMETHASONE (922) POMALIDOMIDE (414) CYCLOPHOSPHAMIDE (295) IXAZOMIB (252) THALIDOMIDE (241) CARFILZOMIB (233) DARATUMUMAB (224) MELPHALAN (112) DOXORUBICIN (84)

Which LENALIDOMIDE Alternatives Have Lower Plasma cell myeloma recurrent Risk?

LENALIDOMIDE vs LENIOLISIB LENALIDOMIDE vs LENOGRASTIM LENALIDOMIDE vs LENVATINIB LENALIDOMIDE vs LEPONEX LENALIDOMIDE vs LERCANIDIPINE

Related Pages

LENALIDOMIDE Full Profile All Plasma cell myeloma recurrent Reports All Drugs Causing Plasma cell myeloma recurrent LENALIDOMIDE Demographics